Cantor Fitzgerald Predicts ZVRA FY2025 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Zevra Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the company will post earnings per share of $1.88 for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter last year, the firm earned ($0.40) EPS.

A number of other equities analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Canaccord Genuity Group reduced their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, Guggenheim began coverage on Zevra Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Trading Down 0.6 %

NASDAQ ZVRA opened at $8.10 on Thursday. The firm has a market cap of $432.38 million, a PE ratio of -4.11 and a beta of 2.01. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a 50 day moving average price of $8.66 and a 200 day moving average price of $7.83.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC boosted its holdings in shares of Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after acquiring an additional 5,940 shares during the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Zevra Therapeutics in the third quarter valued at $92,000. XTX Topco Ltd acquired a new stake in Zevra Therapeutics during the 3rd quarter worth about $94,000. Intech Investment Management LLC purchased a new position in shares of Zevra Therapeutics during the 3rd quarter valued at about $95,000. Finally, SG Americas Securities LLC acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at about $105,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.